On July 20th, 2023, the Federal Reserve launched FedNow, which could spark the fuse for a Digital Dollar. If a Digital Dollar happens, the government could: Monitor every transaction, keep track of your spending habits, and potentially control your individual choices… Which MAY steal your freedoms in one way or another. And if you don’t plan for this now... Your retirement savings could be at risk of being frozen, hacked, or deleted.

You’ll want to act fast... Because with Biden’s long history of voting against Americans... Who knows how much longer until Biden strikes again!

Get your hands on this FREE Wealth Protection Kit today and learn how you could shield your savings and investments before it’s too late!

CVKD Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 58.12%

Insider Buying (Last 12 Months): $111,000.00

Insider Selling (Last 12 Months): $0.00

Cadrenal Therapeutics Insider Trading History Chart

Cadrenal Therapeutics Share Price & Price History

^$0.68

▲ +0.01 (1.49%)

As of 09/29/2023 01:00 AM ET

Days: 30 | 90 | 365

Better Than Oil Stocks

From Oxford Club | Ad

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

CLICK HERE TO FIND OUT MORE

Cadrenal Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/1/2023	Quang X Pham	CEO	Buy	70,000	$0.91	$63,700.00	3,370,000
3/21/2023	John Raymond Murphy	Director	Buy	10,000	$1.39	$13,900.00	594,792
3/16/2023	John Raymond Murphy	Director	Buy	20,000	$1.67	$33,400.00	574,792

Better Than Oil Stocks

From Oxford Club | Ad

The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.

CLICK HERE TO FIND OUT MORE

SEC Filings (Institutional Ownership Changes) for Cadrenal Therapeutics (NASDAQ:CVKD)

4.57% of Cadrenal Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Today's Range

Now: $0.68

$0.68

$0.74

50 Day Range

MA: $0.79

$0.67

$1.06

52 Week Range

Now: $0.68

$0.65

$6.75

Volume

5,563 shs

Average Volume

77,439 shs

Market Capitalization

$8.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cadrenal Therapeutics?: Cadrenal Therapeutics' top insider investors include:
Quang X Pham (CEO)
John Raymond Murphy (Director)
Learn More about top insider investors at Cadrenal Therapeutics.